Abstract CT017: A phase I study evaluating safety, pharmacokinetics, and clinical activity of the novel, paradox breaker BRAF inhibitor RG6344 in patients with BRAF V600-mutant solid tumors
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Maria Vieito, Elisa Fontana, Catherine Han, Eduardo Castanon, David J Pinato, Oliver Bechter, Irene Moreno, Rikke L Eefsen, Ruth Plummer, Reinhard Dummer, Hans Prenen, Giulia Pretelli, Gabriel Schnetzler, Piergiorgio Pettazzoni, Abiraj Keelara, David Dejardin, Andreas Roller, Ernesto Guarin, Elisa Cinato, Tomi Fakolade, Nino Keshelava, Ting Liu, Nick Flinn, Nicole A. Kratochwil
Institutions: Vall d'Hebron Institute of Oncology, Sarah Cannon Research Institute, University of Auckland, New Zealand Clinical Research, Clinica Universidad de Navarra, Hammersmith Hospital, Universitair Ziekenhuis Leuven, Hospital Universitario HM Sanchinarro, Herlev Hospital, Gentofte Hospital, University Hospital Zurich, Antwerp University Hospital, Roche (Switzerland), Roche (United Kingdom)
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4409822402